Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record.

Expression of the ERBB3 gene product in breast cancer

Open access
Lemoine, NR, Barnes, DM, Hollywood, DP, Hughes, CM, Smith, P, Dublin, E, Prigent, SA, Gullick, WJ, Hurst, HC·1992·British Journal of Cancer

Abstract

Abnormalities of the EGF receptor and/or the related ERBB2 receptor occur in a significant proportion of cases of human breast cancer and are important influences in the behaviour of this tumour type. In this report we demonstrate by nucleic acid analysis and immunohistochemistry that the recently recognised third member of this gene family, ERBB3, shows a wide range of expression in breast cancer, and shows stronger immunoreactivity than that observed in normal tissue in 43 out of 195 cases (22%) of primary breast cancer. Overexpression of ERBB3 appears to result from increased levels of gene transcription since in none of the cell lines or primary cancers analysed did we find evidence of gene amplification. High expression of ERBB3 is positively associated with the presence of lymph node metastases, but there was no demonstrable relationship with patient survival in this series.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.1992.420

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 234

Metadata

Authors
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H.
Venue
British Journal of Cancer
Published
1992-12
Volume
66
Issue
6
Pages
1116-1121
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1993373872
Cited by
234
References
0
FWCI
5.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expression of the ERBB3 gene product in breast cancer. https://app.cochat.ai/papers/10.1038/bjc.1992.420
The paper
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H. (1992). Expression of the ERBB3 gene product in breast cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.1992.420

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.